GENITAL CONDYLOMA ACUMINATA IN ELDERLY WOMAN TREATED WITH TOPICAL IMIQUIMOD 5% CREAM: A CASE REPORT
DOI:
https://doi.org/10.66344/jpad.32.1.2022.1830Abstract
Introduction: Condyloma acuminata (CA) is the most common sexually transmitted infection caused by human papillomavirus (HPV). Transmission mainly through sexual intercourse and affects the population between the ages of 25 and 44, although it can occur in older people. Treatments that can be administered are podophyllin, trichloroacetic acid (TCA), imiquimod, 5-fluorouracil, and surgery. Self-administered topical imiquimod has a low recurrence rate. Case report: A 64-year-old woman presents with genital warts since 5 years ago. It was painless and did not bleed easily. Venereology status revealed multiple verrucous papules. Discussion: Genital warts didn’t achieve complete clearance, getting bigger and growing in numbers. Trichloroacetic acid and podophyllin had been administered to the patient once a week for the past 2 years, the warts have decreased in size and then grow again. The patient was advised to undergo surgery, but the patient refused. Then, the patient was given imiquimod 5% cream, 3 times a week for 24 weeks. There was no recurrence after 1 year discontinuation of treatment. Conclusion: A case of genital condyloma acuminata has been reported in elderly woman who was treated with imiquimod 5% cream for 24 weeks and showed a significant improvement.Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.